Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus MECLIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus MECLIZINE HYDROCHLORIDE.
CLARITIN REDITABS vs MECLIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
10 mg orally once daily.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Category C
Category A/B
Antihistamine
Antihistamine